Svein Lien appointed new CEO of Biotec Pharmacon ASA

12-Mar-2010 - Norway

Svein Lien has been appointed new CEO of Biotec Pharmacon, following Lars Viksmoen's decision to resign after 3 years as CEO. Svein Lien will assume the position with effect from 15 March, 2010.

Svein Lien (55) joins the company with a financial background and extensive experience from technology- and diagnostics businesses, most recently as CEO of Axis-Shield plc, the diagnostic company listed in London and Oslo.

"I am very much looking forward to this challenge" Svein Lien says. "I know the company very well from several years as a Board Member and have always been very confident with the technology platform and admired the highly skilled and talented organization. I also have a strong faith in the opportunities created by the close relation to the research community in Tromsø. We will need some more time to conclude on the roote cause behind the disappointing Phase III results and to clarify the strategic route forward. Following that we will inform the market, most likely via a capital market day in Q2."

Other news from the department people

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures
View topic world
Topic world Diagnostics

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 products
1 whitepaper
1 brochures